Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances study located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://keikoc473otw3.ja-blog.com/profile